Main Article Content
Corticosteroids and melphalan were used for decades to treat multiple myeloma. Combination chemotherapy has been extensively studied with similar overall survival rates to melphalan and prednisone. In the last decade, the development of new agents has progressed significantly. Thalidomide and its newer derivatives lenalidomide, bortezomib, and pegylated liposomal doxorubicin have drastically revolutionized treatment approaches. As a result, numerous clinical trials have yielded exciting treatment strategies resulting in therapeutic advances, and improved responses and overall survival of patients. This review summarizes the international uniform response criteria for multiple myeloma and gives a historical perspective on previous therapies with updates on the newest available treatments.
Downloads month by month
Download data is not yet available.
How to Cite
Harandi, A., & Laber, D. A. (2011). Historical perspective and advances in the treatment of multiple myeloma. Oncology Reviews, 2(4), 250-258. https://doi.org/https://doi.org/10.4081/oncol.2008.250
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.